Metabolic · 99.82% Purity
Retatrutide Research Peptide
Retatrutide is a triple hormone receptor agonist that targets the GIP, GLP-1, and glucagon receptors simultaneously, studied in advanced metabolic and body-weight research.
$145.00 · 10mg · Research Use Only
Research Applications
Metabolic pathway modulation, adipogenesis inhibition, energy expenditure studies.
Specifications
Size
10mg
Purity
99.82%
Batch
26030313
Verified By
Janoshik Analytical
Research Overview
Retatrutide (LY3437943) is a first-in-class triple agonist of the GIP, GLP-1, and glucagon receptors. In a Phase 2 clinical trial published in the New England Journal of Medicine (2023), participants receiving retatrutide achieved up to 17.5% mean weight reduction at 24 weeks — among the highest reported for any pharmacological intervention in obesity research to date. Preclinical studies demonstrate its role in suppressing adipogenesis and increasing whole-body energy expenditure through complementary receptor pathways.
Certificate of Analysis
View Certificate of Analysis (PDF) — batch 26030313, verified by Janoshik Analytical at 99.82% purity.
Published research
- Retatrutide Phase 2 Trial — Weight Reduction in Adults with Obesity — New England Journal of Medicine · 2023 · PubMed/NCBI
- Triple Hormone Receptor Agonism: GIP, GLP-1 and Glucagon Receptor Biology — PubMed / NCBI · 2022–2024 · PubMed/NCBI
For laboratory research use only. Not for human consumption.